Abstract
The past 30 years have witnessed tremendous progress in our ability to diagnose and treat osteoporosis. Once considered an inevitable consequence of ageing, osteoporosis can now be accurately diagnosed using dual-energy x-ray absorptiometry (DXA). Fundamental advances in the understanding of the pathogenesis of osteoporosis have driven the development of highly effective treatments, including four bisphosphonates (alendronate, risedronate, ibandronate, and zole-dronate), a human monoclonal anti-body to the receptor activator of nuclear factor κB ligand (denosumab), parathyroid hormone/parathyroid hormone-related peptide analogues (teriparatide and abaloparatide), and a humanised monoclonal antibody to sclerostin (romosozumab).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
